Communiqués DiaMedica Therapeutics Inc.

Actions

DMAC

CA25253X2077

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
8,270 ^USD	+0,85 %		+9,39 %	+3,89 %

11/08	Transcript : DiaMedica Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026
10/08	DiaMedica Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

30/09	DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results	BU
02/09	DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences	BU
10/08	DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights	BU
04/08	DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026	BU
17/07	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
23/06	DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction	BU
16/06	DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program	BU
27/05	DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026	BU
20/05	DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial	BU
12/05	DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	BU
06/05	DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights	BU
30/04	DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026	BU
07/04	RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms	AQ
30/03	DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights	BU
23/03	DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026	BU
05/03	DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia	BU
24/02	DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences	BU
19/01	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
16/01	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
18/12	DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA	BU
12/11	DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights	BU
10/11	DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London	BU
06/11	DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025	BU
29/09/25	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
08/09/25	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences	AQ